Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions

R. Y. Pan, R. L. Dao, S. I. Hung, W. H. Chung*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

34 Scopus citations

Abstract

Cutaneous idiosyncratic drug reactions (CIDRs) are usually unpredictable, ranging from mild maculopapular exanthema (MPE) to severe cutaneous adverse drug reactions (SCARs) such as drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). Increasing evidence suggests that HLA alleles are strongly associated with drug-induced-CIDRs. The pathomechanisms for CIDRs include genetic polymorphisms affecting complex immune-specific HLA/drug antigen/T-cell receptor interactions and drug metabolism. Pharmacogenomic tests to prevent CIDRs have been widely implemented in clinical practice in recent years.

Original languageEnglish
Pages (from-to)86-97
Number of pages12
JournalClinical Pharmacology and Therapeutics
Volume102
Issue number1
DOIs
StatePublished - 01 07 2017

Bibliographical note

Publisher Copyright:
© 2017 American Society for Clinical Pharmacology and Therapeutics

Fingerprint

Dive into the research topics of 'Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions'. Together they form a unique fingerprint.

Cite this